{"product_id":"cagrilintide-semaglutide-10-mg","title":"CAGRILINTIDE + SEMAGLUTIDE","description":"\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:0 0 .4em;font-family:inherit;\"\u003eWhat it is\u003c\/p\u003e\n\u003cp style=\"font-size:1.12em;line-height:1.7;margin:0 0 1em;\"\u003eThe \u003cstrong\u003ebody's two satiety pathways, in a single vial\u003c\/strong\u003e. It combines the amylin analog with the most studied GLP-1 analog in the world. In the literature it is known as CagriSema.\u003c\/p\u003e\n\u003cp style=\"font-size:1.02em;line-height:1.7;margin:0 0 1.2em;color:#374151;\"\u003eThe body has two different systems for saying “enough”: incretins, which come from the gut, and amylin, which comes from the pancreas. Each one works on its own. This combination activates both at once, which is why the combined effect is greater than that of either one separately.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat it is used for\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Research on weight control through two simultaneous pathways\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Satiety, appetite and gastric emptying\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Studies of the combination versus each component separately\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Body composition and cardiometabolic risk factors\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it is used\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:12px;margin:0 0 1.4em;flex-wrap:wrap;\"\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eCycle\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eContinuous until target\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eBreak\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eNot required\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eRoute\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eWeekly subcutaneous\u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eLyophilized powder with both peptides already combined. It is reconstituted with bacteriostatic water, swirled without shaking, and stored between 2 and 8 °C. In clinical trials it is administered once a week with gradual escalation \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat has been observed\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;color:#6b7280;font-size:.95em;\"\u003eResults described in the published scientific literature. They are not directions for use or health recommendations.\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  In the phase 3 REDEFINE 1 trial (3,417 adults, 68 weeks), the mean weight reduction was \u003cstrong\u003e20.4%\u003c\/strong\u003e versus 3.0% with placebo \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Participants reached weight loss targets of 5%, 20%, 25% and even 30% of body weight far more often \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  For reference, semaglutide alone reached 14.9% at 68 weeks in STEP 1, and cagrilintide alone 10.8% in its phase 2 \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[5]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Digestive effects were frequent (79.6% versus 39.9% with placebo), but mostly transient and mild to moderate in intensity \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  An analysis of REDEFINE 1 also described a reduction in blood pressure \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[7]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  There are also phase 3 data in people with type 2 diabetes \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it works\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eSemaglutide — GLP-1 receptor agonist\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eAn analog of the incretin GLP-1 with substitutions that extend its half-life enough to allow weekly administration. It acts on the hypothalamic appetite centers and on glucose-dependent insulin secretion \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eCagrilintide — amylin analog\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eA long-acting amylin analog designed to resist degradation \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[6]\u003c\/sup\u003e. It acts on amylin and calcitonin receptors in the area postrema and slows gastric emptying \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eWhy they add up\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eIncretins and amylin are independent signaling systems that converge on the same behavior: stopping eating. The phase 1b trial already described an additive effect, and phase 3 confirmed it versus each component separately \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eState of the evidence\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eBest in its category.\u003c\/strong\u003e Phase 3 published in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e with more than three thousand participants, additional data in type 2 diabetes and secondary analyses on blood pressure \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[7]\u003c\/sup\u003e. Even so, the combination is not approved as a medicine, and the material we offer is research grade, not pharmaceutical grade.\u003c\/p\u003e\n\n\u003cp style=\"margin:1.6em 0 0;padding:12px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e⚠️ Product intended exclusively for \u003cstrong\u003eresearch and laboratory use\u003c\/strong\u003e. Not for human or veterinary consumption.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eReferences\u003c\/p\u003e\n\u003col style=\"margin:0;padding-left:1.4em;font-size:.86em;color:#6b7280;line-height:1.7;\"\u003e\n  \u003cli\u003eGarvey WT, et al. \u003cem\u003eCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.\u003c\/em\u003e N Engl J Med, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544433\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40544433\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eDavies MJ, et al. \u003cem\u003eCagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.\u003c\/em\u003e N Engl J Med, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544432\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40544432\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eEnebo LB, et al. \u003cem\u003eSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.\u003c\/em\u003e Lancet, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33894838\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 33894838\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eWilding JPH, et al. \u003cem\u003eOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).\u003c\/em\u003e N Engl J Med, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33567185\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 33567185\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLau DCW, et al. \u003cem\u003eOnce-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 dose-finding trial.\u003c\/em\u003e Lancet, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 34798060\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eKruse T, et al. \u003cem\u003eDevelopment of Cagrilintide, a Long-Acting Amylin Analogue.\u003c\/em\u003e J Med Chem, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34288673\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 34288673\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eVerma S, et al. \u003cem\u003eCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.\u003c\/em\u003e Hypertension, 2026. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41328546\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 41328546\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"Peptido Biogenetic","offers":[{"title":"10 mg","offer_id":55005234037065,"sku":"CS10","price":218.18,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1016\/7507\/3865\/files\/cagrilintide-semaglutide-10-mg-sin-fondo.png?v=1787687090","url":"https:\/\/www.peptidobiogenetic.com\/en-us\/products\/cagrilintide-semaglutide-10-mg","provider":"PeptidoBioGenetic","version":"1.0","type":"link"}